Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.
The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...
The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...
Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...
Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People
MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...
The predictive value of the multitarget stool DNA (mt-sDNA) test is unaffected by the presence of known colorectal cancer (CRC) risk factors, suggesting it could be used in patients at increased risk ...
The US Food and Drug Administration (FDA) has approved an improved stool collection kit of Geneoscopy’s RNA-based colorectal cancer (CRC) screening test, ColoSense. The new kit enhances user ...
WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
Results of multi-institutional clinical study published in peer reviewed journal ‘Cancers’ confirms efficacy of Oxford BioDynamics’ EpiSwitch ® blood-based Colorectal No-Stool Test (NST) High accuracy ...
ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback